Event Participants
Executives
4
M. Satish Choudhury (Company Secretary & CIR), Dr. Kiran S. Divi (Whole-Time Director & CEO), Nilima Prasad Divi (Whole-Time Director - Commercial), Venkatesa Perumallu Pasumarthy (CFO)
Analysts
12
Bino Pathiparampil (Elara Capital), Damayanti Kerai (HSBC Bank), Dhawal Khut (Jefferies), Kunal Dhamesha (Macquarie), Neha Gupta (Bank of America), Rahul Jeewani (IIFL Securities), Saurabh Mukherjea (Devas Consultant), Shyam Srinivasan (Goldman Sachs), Suryanarayana Patra (PhillipCapital), Tirumala Reddy (Individual Investor), Tushar Manudhane (Motilal Oswal), Vivek Agrawal (Citigroup)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Total Income | ₹3,144 crores | +24.3% YoY vs ₹2,529 crores; driven by strong custom synthesis growth |
| Consolidated PBT | ₹1,180 crores | +61.0% YoY vs ₹733 crores; margin expansion from product mix |
| Consolidated PAT | ₹902 crores | +65.5% YoY vs ₹545 crores |
| Standalone Total Income | ₹3,037 crores | +22.7% YoY vs ₹2,476 crores; +10% constant currency growth |
| Standalone PBT | ₹1,165 crores | +55.9% YoY vs ₹747 crores |
| Standalone PAT | ₹895 crores | +60.7% YoY vs ₹557 crores |
| Business Mix | CS: 60% / Generics: 40% | Shift toward higher-margin custom synthesis; mix varies quarterly |
| Net Material Consumption | 31.2% of standalone revenue | Reflecting integrated manufacturing model benefits |
| Forex Gain/Loss | Net loss of ₹7 crores | Vs net gain of ₹39 crores in Q1 FY26; INR depreciation partially offset |
| Nutraceutical Revenue | ₹298 crores | +19.2% YoY vs ₹250 crores; 20th year in segment with 100+ products |
| Capital Expenditure | ₹451 crores capitalized | CWIP at ₹2,034 crores as of June 30, 2026 |
| Cash & Equivalents | ₹3,611 crores | As of quarter end |
| Trade Receivables | ₹3,056 crores | As of quarter end |
| Inventories | ₹4,413 crores | Elevated due to strategic 3-month buffer stocking & validation batches |
Geographic & Segment Commentary
Custom Synthesis & CDMO: Revenue contribution at 60% of total, up significantly YoY. Three major CapEx programs near completion with validations ongoing; multiple projects across clinical development, validations, and commercial supply preparations. Dedicated projects have shipped validation quantities to customers; commercial ramp-up awaits regulatory qualifications/approvals. ~18-20 projects commercialized or being commercialized, with healthy pipeline across therapeutic areas.
Generics & Nutraceuticals: Generic volumes remained stable with continued pricing pressure across geographies; segment contributed 40% of revenue. Pricing dynamics reflect raw material cost pass-throughs (solvent costs nearly doubled/tripled) rather than true market recovery. Nutraceutical business grew 19.2% YoY to ₹298 crores, now 20 years in segment with portfolio of 100+ offerings across human health, animal health, and dietary supplements. Four DMFs filed in recent years with customers undergoing qualification; commercial volumes expected in 3-6 months for products like Ticagrelor, Viverac, and Racetam.
Geography: Exports accounted for ~90% of standalone revenue; Europe and North America comprised 75% of exports.
Company-Specific & Strategic Commentary
Backward Integration & Unit 3: Unit 3 (Kakinada) playing expanding role in production network, supporting backward integration through selected pre-chemistry operations and phase transfers from existing facilities. Enhances supply assurance for critical intermediates and improves network flexibility. Long-term plan includes qualifying Kakinada with regulatory clearances; interim strategy involves filling plant with pre-chemistry products. Facility utilization across all three units at ~80-85%.
Peptide Strategy: Peptides remain strategic investment area with customer programs progressing across development stages. Built complete backward integration chain from basic raw materials including protected amino acids, dipeptides, tripeptides, and fragments. Currently expanding capacity by installing multiple 3,000-liter SPPS (solid-phase peptide synthesis) units. Ambition to be largest integrated peptide player globally; competitive edge from in-house Fmoc/Boc amino acids and resin manufacturing. Qualification and validation for several peptide fragments expected to advance over coming quarters alongside capacity expansion in both SPPS and LPPS.
CapEx Program Completion: Three major CapEx programs nearing completion with validations ongoing. Total program size approximately ₹2,000 crores with ~70% capitalized to date. Capitalized assets of ₹451 crores during Q1 FY27; CWIP at ₹2,034 crores.
Supply Chain Resilience: Strategic shift from just-in-time to 3-month rolling inventory stocking initiated around March 2026 to ensure production continuity amid Middle East geopolitical uncertainty. Enhanced procurement resilience through diversified global supplier base and expanded domestic sourcing. No production losses or shipment stoppages experienced despite challenging conditions.
Technology Development: Continued investment in continuous-flow chemistry, biocatalysis, and advanced automation. Focus on improved process safety, reduced variability, and sustainable manufacturing routes for complex chemistries.
Contrast Media: Iodine-based contrast media – signing long-term multi-year contracts with two customers; commercialization started for one, second expected within months. Gadolinium – project at clinical phase with customer; awaiting regulatory approvals, progressing at slower pace.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (FY27) | Double-digit growth assurance | Management committed to double-digit growth; upside dependent on speed of regulatory approvals for validated projects |
| Gross Margin | ~60% for full year; Q1 at ~68% | Q1 elevated due to CS-heavy mix (60%); lumpiness expected quarterly |
| EBITDA Margin | Similar to last year | Management advises viewing on annual basis, not quarterly |
| Commercial Ramp-up | 3-6 months for generic DMF products | Multiple customers qualifying; commercial volumes expected once qualification completes |
| CS Revenue Mix | Variable (60/40 to 50/50) | Depending on validation/commercialization timing and regulatory approval pace |
Risks & Constraints
| Risk | Context |
|---|---|
| Solvent Cost Inflation | Solvent prices nearly doubled/tripled due to Middle East geopolitical tensions; directly impacting RM costs and inventory valuation. Costs remain volatile with no clear normalization timeline. Management holds strategic 3-month inventory buffers at higher costs to prevent production stoppages. |
| Regulatory Approval Delays | Commercial ramp-up of three major validated CapEx projects depends on customer filings, agency approvals, and possible inspections. Timeline uncertain ("will FDA come for inspection? I cannot answer for the agency"). Delays would postpone commercial volumes and revenue inflection. |
| Geopolitical Supply Chain Disruption | West Asia situation creating uncertainty in global trade routes, sourcing channels, container availability, port congestion, and extended transit times. Freight rates remain elevated across ocean and air. |
| Competitive CDMO Pressure | New entrants consolidating into CDMO segment; however, management emphasizes track record, EHS capabilities, and reputation as differentiators over pricing. |
| Inventory Valuation Risk | Elevated inventories (₹4,413 crores) at higher costs; if input prices normalize, inventory write-downs or margin compression possible. |
| Customer Concentration in CS | Bound by CDMO confidentiality agreements limiting disclosure; heavy concentration in a few large validation projects increases dependency risk. |
Q&A Highlights
Custom Synthesis Growth & Validation Projects
- Question: Is the strong CS growth driven by dedicated CapEx projects or existing operations? (Kunal Dhamesha, Macquarie)
- Answer: Validation batches of the three major CapEx projects have been partially shipped to customers; multiple projects are in the pipeline. Management is bound by CDMO confidentiality on quantities, product names, and order book values. (Kiran S. Divi)
- Question: What's the historical ratio of validation quantities to commercial ramp-up volumes? (Kunal Dhamesha, Macquarie)
- Answer: Varies significantly by product—annual demand ranges from 1,000 kg to 5,000-6,000 tons depending on product and dosing. Cannot generalize. (Kiran S. Divi)
Regulatory Milestones for Dedicated Projects
- Question: What are the key milestones before commercial supply begins? Will FDA inspection be required? (Suryanarayana Patra, PhillipCapital)
- Answer: Regulatory clearances are definitely required since these are not raw materials. Management is "completely ready" for regulatory submissions and inspections but cannot predict agency timelines. Clarity will emerge once customer filings progress. (Kiran S. Divi)
Margins & Inventory Build-up
- Question: The inventory change of ₹500 crores is significantly higher than typical quarterly run-rate; what drove this? (Damayanti Kerai, HSBC)
- Answer: Two factors: (1) Strategic decision since March 2026 to maintain 3-month rolling inventory buffer to prevent production stoppages, secured at higher costs; (2) Validation batches for new CapEx projects reflected in inventory. This strategy will continue while uncertainty persists. (Nilima Prasad Divi)
- Question: Should incremental inventory change of ₹300-400 crores be adjusted to assess sustainable margins (implying 55-58% gross margin)? (Rahul Jeewani, IIFL)
- Answer: Inventory increase includes not just raw materials but also work-in-progress, intermediates, and finished goods; higher raw material prices inflate all inventory components. No clear guidance on normalization timeline given macro uncertainty. (Nilima Prasad Divi)
Generic Pricing Environment
- Question: Is June data showing positive inflection in generic API pricing indicative of end of pricing pressure cycle? (Shyam Srinivasan, Goldman Sachs)
- Answer: The apparent price increases are largely due to raw material cost pass-throughs (solvents nearly doubled/tripled) and market corrections making products viable, not true pricing recovery. Company has selectively raised prices where feasible. (Kiran S. Divi)
Peptide Competitive Positioning
- Question: Given backward integration advantages, how many global CDMOs can compete with Divi's over next 3-4 years? (Kunal Dhamesha, Macquarie)
- Answer: Cannot comment on competitors, but Divi's is uniquely positioned as the only player manufacturing from basic raw materials through protected amino acids, dipeptides, tripeptides, and fragments with complete backward integration. "Amazing opportunities" in fragment segment; expanding SPPS capacity with additional 3,000-liter units. (Kiran S. Divi)
Contrast Media Update
- Question: Status of iodine and gadolinium contrast media programs? (Saurabh Mukherjea, Devas Consultant)
- Answer: Iodine—signing long-term multi-year contracts with two customers; commercialization started for one, second starting within months. Gadolinium—still at clinical phase qualification stage (Phase II/III), project progressing slowly with customer; awaiting their regulatory approvals. (Kiran S. Divi)
Unit 3 Role & Utilization
- Question: Will Unit 3 primarily serve backward integration and KSM/intermediate production without commercial supply until regulatory approval? (Damayanti Kerai, HSBC)
- Answer: Kakinada currently supports backward integration to free up regulatory-approved plants (Unit 1 & 2) by handling pre-chemistry work. Long-term plan is qualifying Unit 3 with all regulatory clearances, but FDA qualification for new facility could take 1-2 years. Overall utilization across three units is ~80-85%. (Kiran S. Divi, Nilima Prasad Divi)
Full Year Margin Guidance
- Question: Can you provide full-year margin guidance relative to last year? (Bino Pathiparampil, Elara Capital)
- Answer: Gross margin approximately 60% for full year; Q1 at ~68% is not sustainable run-rate due to CS-heavy mix. EBITDA margin expected "similar as last year." Lumpiness expected across quarters. (Nilima Prasad Divi, Kiran S. Divi)
Key Takeaway
Divi's Laboratories posted robust Q1 FY27 results with consolidated revenue of ₹3,144 crores (+24.3% YoY) and PAT of ₹902 crores (+65.5% YoY), driven by custom synthesis strength (60% of mix) where three major CapEx programs (~₹2,000 crores, ~70% capitalized) have completed validations with commercial ramp-up pending regulatory approvals. The company maintains its double-digit growth assurance for FY27, though management cautions on quarterly lumpiness and expects full-year gross margins around 60% versus Q1's elevated 68%. Strategic priorities include peptide expansion (installing additional 3,000-liter SPPS units) leveraging complete backward integration from basic raw materials, Unit 3's growing role in backward integration with utilization at 80-85% across facilities, and iodine contrast media long-term contracts beginning commercialization. Key watch points: solvent cost inflation from Middle East tensions (prices nearly doubled/tripled), 3-month rolling inventory buffers elevating working capital, and regulatory approval timelines governing CS commercial inflection.